One-pot expression of an oligoclonal nanobody-based antivenom in growth-decoupled Escherichia coli
Trends in Biotechnology · 2026
DOI: 10.1016/j.tibtech.2026.02.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Biotechnology, 2026. Verfasst von Patrick Stargardt und 9 weiteren Autor:innen. Beteiligte Einrichtung: enGenes Biotech, Vienna 1190, Austria. Hauptthemen laut MEDLINE: Escherichia coli, Antivenins, Single-Domain Antibodies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Austrian Science Fund, Wellcome, Wellcome Trust.
Abstract (Originalsprache)
Oligoclonal VHH mixtures targeting distinct epitopes offer therapeutic benefits in mitigating complex diseases, including cancer, infectious diseases, and snakebite envenoming. However, current production strategies rely on separate expression and purification of individual VHHs, followed by downstream mixing, resulting in high costs. We present a cocultivation approach for producing an experimental recombinant antivenom using growth-decoupled Escherichia coli strains. Six different cell lines were generated by transforming the same host with different VHH genes. The cell lines displayed high-yield extracellular secretion in microtiter plate and 1-l bioreactor cultivations, and cocultivation at defined inoculation ratios yielded oligoclonal VHH mixtures approaching target compositions. This strategy enables one-pot manufacturing with minimal downstream processing and predictable composition. A techno-economic assessment based on obtained titers and two-step purification indicates reduced per-treatment costs compared with Chinese Hamster Ovary cells produced IgG-based antivenoms. Our findings offer an alternative to conventional oligoclonal VHH production for multivalent therapeutics requiring broad neutralization, including recombinant antivenoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- enGenes Biotech, Vienna 1190, Austria.
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby DK-2800, Denmark.
- Department of Biotechnology and Food Science, Institute of Bioprocess Science and Engineering (IBSE), BOKU University, Vienna 1190, Austria.
- Department of Biotechnology and Food Science, Institute of Bioprocess Science and Engineering (IBSE), BOKU University, Vienna 1190, Austria; Austrian Centre of Industrial Biotechnology, Muthgasse 11, Vienna, Austria.
- enGenes Biotech, Vienna 1190, Austria. Electronic address: juergen.mairhofer@engenes.cc.
- Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby DK-2800, Denmark. Electronic address: ahola@bio.dtu.dk.
Förderung
- Austrian Science Fund
- Wellcome
- Wellcome Trust
Zitieren
APA
Stargardt, P., Ljungars, A., Scheich, D., Lingg, N., Elmose, E. S., Ahmadi, S., Simon, F., Jungbauer, A., Mairhofer, J., & Laustsen, A. H. (2026). One-pot expression of an oligoclonal nanobody-based antivenom in growth-decoupled Escherichia coli. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2026.02.022
Vancouver
Stargardt P, Ljungars A, Scheich D, Lingg N, Elmose ES, Ahmadi S, et al. One-pot expression of an oligoclonal nanobody-based antivenom in growth-decoupled Escherichia coli. Trends in Biotechnology. 2026. doi:10.1016/j.tibtech.2026.02.022
BibTeX
@article{Stargardt2026,
author = {Stargardt, Patrick and Ljungars, Anne and Scheich, David and Lingg, Nico and Elmose, Emil S and Ahmadi, Shirin and Simon, Florian and Jungbauer, Alois and Mairhofer, Juergen and Laustsen, Andreas H},
title = {One-pot expression of an oligoclonal nanobody-based antivenom in growth-decoupled Escherichia coli},
journal = {Trends in Biotechnology},
year = {2026},
doi = {10.1016/j.tibtech.2026.02.022}
}
EUVIMED